Cellular Immune Profiling of Lung and Blood Compartments in Patients with SARS-CoV-2 Infection.
BALF
PBMC
SARS-CoV-2
cellular immune profile
severe COVID-19
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
11 Mar 2023
11 Mar 2023
Historique:
received:
28
01
2023
revised:
07
03
2023
accepted:
08
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
SARS-CoV-2 related immunopathology may be the driving cause underlying severe COVID-19. Through an immunophenotyping analysis on paired bronchoalveolar lavage fluid (BALF) and blood samples collected from mechanically ventilated patients with COVID-19-associated Acute Respiratory Distress Syndrome (CARDS), this study aimed to evaluate the cellular immune responses in survivors and non-survivors of COVID-19. A total of 36 paired clinical samples of bronchoalveolar lavage fluid (BALF) mononuclear cells (BALF-MC) and peripheral blood mononuclear cells (PBMC) were collected from 18 SARS-CoV-2-infected subjects admitted to the intensive care unit (ICU) of the Policlinico Umberto I, Sapienza University Hospital in Rome (Italy) for severe interstitial pneumonia. The frequencies of monocytes (total, classical, intermediate and non-classical) and Natural Killer (NK) cell subsets (total, CD56 Survivors with CARDS exhibited higher frequencies of classical monocytes in blood compared to non-survivors ( These results show that the immune cellular profile in blood and pulmonary compartments was similar in survivors and non-survivors of COVID-19. T lymphocyte levels were reduced, but resulted highly immune-activated in the lung compartment of patients who faced a fatal outcome.
Sections du résumé
BACKGROUND
BACKGROUND
SARS-CoV-2 related immunopathology may be the driving cause underlying severe COVID-19. Through an immunophenotyping analysis on paired bronchoalveolar lavage fluid (BALF) and blood samples collected from mechanically ventilated patients with COVID-19-associated Acute Respiratory Distress Syndrome (CARDS), this study aimed to evaluate the cellular immune responses in survivors and non-survivors of COVID-19.
METHODS
METHODS
A total of 36 paired clinical samples of bronchoalveolar lavage fluid (BALF) mononuclear cells (BALF-MC) and peripheral blood mononuclear cells (PBMC) were collected from 18 SARS-CoV-2-infected subjects admitted to the intensive care unit (ICU) of the Policlinico Umberto I, Sapienza University Hospital in Rome (Italy) for severe interstitial pneumonia. The frequencies of monocytes (total, classical, intermediate and non-classical) and Natural Killer (NK) cell subsets (total, CD56
RESULTS
RESULTS
Survivors with CARDS exhibited higher frequencies of classical monocytes in blood compared to non-survivors (
CONCLUSIONS
CONCLUSIONS
These results show that the immune cellular profile in blood and pulmonary compartments was similar in survivors and non-survivors of COVID-19. T lymphocyte levels were reduced, but resulted highly immune-activated in the lung compartment of patients who faced a fatal outcome.
Identifiants
pubmed: 36986364
pii: pathogens12030442
doi: 10.3390/pathogens12030442
pmc: PMC10057444
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : 1) EU funding within the NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases; 2) Ricerca Ateneo Sapienza, Progetti Medi, 2020
ID : 1) (Project no. PE00000007, INF-ACT, Spoke 1, 2 and 4: 2) Protocol Number: RM120172B7C4C0E0
Références
Front Immunol. 2020 Oct 14;11:580237
pubmed: 33154753
J Inflamm Res. 2021 Apr 09;14:1331-1340
pubmed: 33859488
Thorax. 2021 Oct;76(10):1010-1019
pubmed: 33846275
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
Eur J Immunol. 2022 Jul;52(7):1120-1128
pubmed: 35419822
Lancet Infect Dis. 2020 Oct;20(10):1135-1140
pubmed: 32526193
J Immunol Res. 2018 Aug 12;2018:1738676
pubmed: 30186879
Cells. 2022 Oct 04;11(19):
pubmed: 36231087
Front Immunol. 2022 Apr 01;13:864298
pubmed: 35432340
Oxf Open Immunol. 2021 Jul 15;2(1):iqab016
pubmed: 35593707
Medicine (Baltimore). 2020 Sep 04;99(36):e21803
pubmed: 32899009
Clin Immunol. 2020 Aug;217:108486
pubmed: 32479985
Viruses. 2021 Sep 20;13(9):
pubmed: 34578457
Respiration. 2021;100(6):488-498
pubmed: 33725700
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2215-e2227
pubmed: 33484559
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Cell. 2021 Apr 1;184(7):1671-1692
pubmed: 33743212
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Sci Immunol. 2020 Aug 21;5(50):
pubmed: 32826343
J Clin Invest. 2020 Dec 1;130(12):6290-6300
pubmed: 32784290
Clin Infect Dis. 2021 Jan 23;72(1):182-183
pubmed: 32474605
Am J Respir Crit Care Med. 2021 Jan 1;203(1):54-66
pubmed: 33119402
Cell Res. 2021 Mar;31(3):272-290
pubmed: 33473155
Immunity. 2021 Nov 9;54(11):2650-2669.e14
pubmed: 34592166
Immunity. 2021 Apr 13;54(4):797-814.e6
pubmed: 33765436
EClinicalMedicine. 2021 Mar;33:100765
pubmed: 33655204
Front Immunol. 2022 Jul 12;13:873232
pubmed: 35903094
Semin Immunol. 2021 Jun;55:101508
pubmed: 34728121
Hum Pathol. 2021 Jul;113:92-103
pubmed: 33905777
Clin Infect Dis. 2020 Nov 19;71(16):2150-2157
pubmed: 32442287
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Sci Immunol. 2021 Jan 21;6(55):
pubmed: 33478949
Cell Discov. 2021 Mar 23;7(1):17
pubmed: 33758165
Ann Med. 2022 Dec;54(1):1894-1905
pubmed: 35786088
Life Sci. 2021 Mar 15;269:119010
pubmed: 33454368
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
BMC Infect Dis. 2021 Apr 15;21(1):353
pubmed: 33858331
Blood Cells Mol Dis. 2020 Jul;83:102437
pubmed: 32325421
Lancet Respir Med. 2021 Dec;9(12):1377-1386
pubmed: 34653374
Front Immunol. 2020 Dec 15;11:596631
pubmed: 33384690
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
J Intern Med. 2004 Apr;255(4):512-8
pubmed: 15049886
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
J Clin Med. 2022 Jan 28;11(3):
pubmed: 35160150
Signal Transduct Target Ther. 2020 Jul 25;5(1):128
pubmed: 32712629
Infect Genet Evol. 2020 Nov;85:104502
pubmed: 32798769
Front Immunol. 2021 Jul 21;12:720109
pubmed: 34367190
Nat Rev Immunol. 2020 May;20(5):277
pubmed: 32249845
Biomed Pharmacother. 2022 Feb;146:112592
pubmed: 35062063
Biol Sex Differ. 2020 May 1;11(1):23
pubmed: 32357901
Cell Commun Signal. 2022 Jun 2;20(1):79
pubmed: 35655192